Type 2 diabetes mellitus and risk of hepatocellular carcinoma: Spotlight on nonalcoholic fatty liver disease

Annals of Translational Medicine

Volumn 5, Issue 13, 2017, Pages

  Mantovani, Alessandro ^a   Targher, Giovanni ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Cancer; Diabetes; Hepatocellular carcinoma (HCC); Nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; METFORMIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; SULFONYLUREA DERIVATIVE;

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; DRUG EFFECT; GENE; GENETIC POLYMORPHISM; GENOMIC INSTABILITY; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PNPLA3 GENE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TUMOR VOLUME;

EID: 85024927981     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2017.04.41     Document Type: Review

References (102)

1. Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs:is the fog clearing? Nat Rev Clin Oncol 2017;14:85-99.
2. Tuffier T. Diabete et neoplasmes. Archives generales de medecine 1888;7:129-40.
3. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas:global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
4. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137-149.
5. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
6. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma:present and future. Clin Liver Dis 2011;15:223-43.
7. Zhang H, Gao C, Fang L, et al. Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus. World J Gastroenterol 2013;19:2395-403.
8. Madkhali AA, Fadel ZT, Aljiffry MM, et al. Surgical treatment for hepatocellular carcinoma. Saudi J Gastroenterol 2015;21:11-7.
9. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-55.
10. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012;56:704-13.
11. Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int 2016;36:317-24.
12. Streba LA, Vere CC, Rogoveanu I, et al. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103-10.
13. Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015;19:361-79.
14. Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 2016;65:1151-60.
15. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
16. Lonardo A, Bellentani S, Argo CK, et al. Epidemiological modifiers of non-alcoholic fatty liver disease:focus on high-risk groups. Dig Liver Dis 2015;47:997-1006.
17. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44.
18. Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015;100:2231-38.
19. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-S64.
20. Sudharsanan N, Ali MK, Mehta NK, et al. Population aging, macroeconomic changes, and global diabetes prevalence, 1990-2008. Popul Health Metr 2015;13:33.
21. Leahy S, O'Halloran AM, O'Leary N, et al. Prevalence and correlates of diagnosed and undiagnosed type 2 diabetes mellitus and pre-diabetes in older adults:findings from the Irish Longitudinal Study on Ageing (TILDA). Diabetes Res Clin Pract 2015;110:241-49.
22. Kaaks R, Kühn T. Epidemiology:obesity and cancer-the evidence is fattening up. Nat Rev Endocrinol 2014;10:644-45.
23. Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012:a population-based study. Lancet Oncol 2015;16:36-46.
24. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer:umbrella review of meta-analyses of observational studies. BMJ 2015;350:g7607.
25. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41.
26. Verlato G, Zoppini G, Bonora E, et al. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 2003;26:1047-51.
27. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012;55:948-58.
28. Geier AS, Wellmann J, Wellmann I, et al. Cancer detection rates following enrolment in a disease management program for type 2 diabetes. Diabetologia 2013;56:1944-48.
29. Tseng CH. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011;34:616-21.
30. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010;47:87-95.
31. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-21.
32. Johnson JA, Bowker SL, Richardson K, et al. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011;54:2263-71.
33. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
34. Lawson DH, Gray JM, McKillop C, et al. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 1986;61:945-55.
35. La Vecchia C, Negri E, D'Avanzo B, et al. Medical history and primary liver cancer. Cancer Res 1990;50:6274-77.
36. Fujino Y, Mizoue T, Tokui N, et al. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev 2001;17:374-79.
37. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma:a case-control study among United States Veterans. Am J Gastroenterol 2001;96:2462-67.
38. Yu L, Sloane DA, Guo C, et al. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol 2006;4:355-60.
39. Gao C, Yao SK. Diabetes mellitus:a "true" independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int 2009;8:465-73.
40. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma:a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80.
41. Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma:a systematic review and meta-analysis. Diabetes Metab Res Rev 2012;28:109-22.
42. Schlesinger S, Aleksandrova K, Pischon T, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 2013;24:2449-55.
43. Koh WP, Wang R, Jin A, et al. Diabetes mellitus and risk of hepatocellular carcinoma:findings from the Singapore Chinese Health Study. Br J Cancer 2013;108:1182-88.
44. Miele L, Bosetti C, Turati F, et al. Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterol Res Pract 2015;2015:570356.
45. Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients:a systematic review. Dig Dis Sci 2016;61:636-45.
46. Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and resource utilization for HCC:US perspective. Curr Med Res Opin 2010;26:2183-91.
47. Ertle J, Dechêne A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
48. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016;17:E774.
49. Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1.
50. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012;10:1342-59.
51. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
52. Guzman G, Brunt EM, Petrovic LM, et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-6.
53. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19.
54. Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009;44:1190-94.
55. Rahman RN, Ibdah JA. Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: A population based study. Hepatology 2012;56:241A.
56. Alexander J, Torbenson M, Wu TT, et al. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver:a clinical and pathological study. J Gastroenterol Hepatol 2013;28:848-54.
57. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver:role of environmental and genetic factors. World J Gastroenterol 2014;20:12945-55.
58. Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015;21:1189-96.
59. Mohamad B, Shah V, Onyshchenko M, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9.
60. Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012;107:253-61.
61. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007;97:1005-8.
62. Chen Y, Wang X, Wang J, et al. Excess body weight and the risk of primary liver cancer:an updated meta-analysis of prospective studies. Eur J Cancer 2012;48:2137-45.
63. Tanaka K, Tsuji I, Tamakoshi A, et al. Obesity and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2012;42:212-21.
64. Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer 2013;132:645-57.
65. Wainwright P, Scorletti E, Byrne CD. Type 2 diabetes and hepatocellular carcinoma:risk factors and pathogenesis. Curr Diab Rep 2017;17:20.
66. Sakurai T, Maeda S, Chang L, et al. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006;103:10544-51.
67. Hoesel B, Schmid JA. The complexity of NF-B signalling in inflammation and cancer. Mol Cancer 2013;12:86.
68. Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/IKK-gamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007;11:119-32.
69. Li C, Deng M, Hu J, et al. Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget 2016;7:17021-34.
70. Giusy E, Poupak F. Hepatocellular carcinoma and CXCR3 chemokines:a narrative review. Clin Ter 2017;168:e37-e41.
71. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nature Reviews Gastroenterology and Hepatology 2013;10:656-65.
72. Ish-Shalom D, Christoffersen CT, Vorwerk P, et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997;40:S25-S31.
73. Rhee SG, Bae YS, Lee SR, et al. Hydrogen peroxide:a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE 2000;2000:pe1.
74. Yang S, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000;378:259-68.
75. Spickett CM. The lipid peroxidation product 4-hydroxy-2-nonenal:advances in chemistry and analysis. Redox Biol 2013;1:145-52.
76. Hu W, Feng Z, Eveleigh J, et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002;23:1781-89.
77. Adams LA, Morrison M. The microbiome in obesity, diabetes and NAFLD: what is your gut telling us? Curr Hepatol Rep 2016;15:96-102.
78. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-16.
79. Darnaud M, Faivre J, Moniaux N. Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 2013;58:385-7.
80. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101.
81. Ren Z, Xu S, Jiang J, Zheng S. A novel diagnosis for early hepatocellular carcinoma based on intestinal microbiome. 21st Annual Meeting of the International Liver Transplant Society, Chicago, IL, 2015.
82. Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genet 2015;47:505-11.
83. Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.
84. Zain SM, Mohamed R, Cooper DN, et al. Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease. PLoS One 2014;9:e95604.
85. Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 2006;21:15-21.
86. Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013;19:6969-78.
87. Chamoun Z, Vacca F, Parton RG, et al. PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell 2013;105:219-33.
88. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
89. Falleti E, Fabris C, Cmet S, et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011;31:1137-43.
90. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
91. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes, who use sulfonylureas or insulin. Diabetes Care 2006;29:254-58.
92. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer:a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.
93. Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750-8.
94. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938-46.
95. Lai SW, Chen PC, Liao KF, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012;107:46-52.
96. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of hepatocellular cancer:a systematic review and meta-analysis. Am J Gastroenterol 2013;108:881-91.
97. Zhou YY, Zhu GQ, Liu T, et al. Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma. Sci Rep 2016;6:33743.
98. Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 2014;37:2522-32.
99. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838-45.
100. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin:systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-603.
101. Thakkar B, Aronis KN, Vamvini MT, et al. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients:a meta-analysis using primary data of published studies. Metabolism 2013;62:922-34.
102. Yin M, Zhou J, Gorak EJ, et al. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013;18:1248-55.